A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513853-66-00

Acronym

61186372COR3002

Enrollment

162

Registered

2025-01-15

Start date

2025-02-04

Completion date

Unknown

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

Brief summary

PFS (using RECIST v1.1), as assessed by BICR, OS

Interventions

DRUGBEVACIZUMAB

DRUGErbitux 5 mg/mL solution for infusion

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGVEGZELMA 25 mg/mL concentrate for solution for infusion

DRUGJNJ-61186372

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS (using RECIST v1.1), as assessed by BICR, OS	—

Countries

Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026